In the past week, WVE stock has gone down by -4.99%, with a monthly decline of -10.24% and a quarterly plunge of -14.29%. The volatility ratio for the week is 5.31%, and the volatility levels for the last 30 days are 6.11% for Wave Life Sciences Ltd. The simple moving average for the last 20 days is -7.36% for WVE’s stock, with a simple moving average of 1.85% for the last 200 days.
Is It Worth Investing in Wave Life Sciences Ltd. (NASDAQ: WVE) Right Now?
Moreover, the 36-month beta value for WVE is -1.13. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for WVE is 98.13M and currently, short sellers hold a 3.67% of that float. On August 23, 2024, WVE’s average trading volume was 877.86K shares.
WVE) stock’s latest price update
Wave Life Sciences Ltd. (NASDAQ: WVE) has experienced a decline in its stock price by -5.64 compared to its previous closing price of 5.85. However, the company has seen a fall of -4.99% in its stock price over the last five trading days. seekingalpha.com reported 2024-08-10 that Wave Life Sciences Ltd. (NASDAQ:WVE ) Q2 2024 Results Conference Call August 8, 2024 8:30 AM ET Company Participants Kate Rausch – Vice President, Investor Relations & Corporate Affairs Paul Bolno – President & Chief Executive Officer Anne-Marie Li-Kwai-Cheung – Chief Development Officer Kyle Moran – Chief Financial Officer Erik Ingelsson – Chief Scientific Officer Conference Call Participants Tiago Fauth – Wells Fargo Joseph Schwartz – Leerink Partners Steven Seedhouse – Raymond James Luca Issi – RBC Salim Syed – Mizuho Joon Lee – Truist Operator Good morning, and welcome to the Wave Life Sciences Second Quarter 2024 Financial Results Conference Call.
Analysts’ Opinion of WVE
Many brokerage firms have already submitted their reports for WVE stocks, with Wells Fargo repeating the rating for WVE by listing it as a “Overweight.” The predicted price for WVE in the upcoming period, according to Wells Fargo is $11 based on the research report published on May 15, 2024 of the current year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see WVE reach a price target of $12, previously predicting the price at $5. The rating they have provided for WVE stocks is “Outperform” according to the report published on December 19th, 2023.
Raymond James gave a rating of “Outperform” to WVE, setting the target price at $7 in the report published on July 05th of the previous year.
WVE Trading at -4.22% from the 50-Day Moving Average
After a stumble in the market that brought WVE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.03% of loss for the given period.
Volatility was left at 6.11%, however, over the last 30 days, the volatility rate increased by 5.31%, as shares sank -12.38% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.97% lower at present.
During the last 5 trading sessions, WVE fell by -4.99%, which changed the moving average for the period of 200-days by -2.13% in comparison to the 20-day moving average, which settled at $5.92. In addition, Wave Life Sciences Ltd. saw 9.31% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at WVE starting from PAUL BOLNO, who proposed sale 48,366 shares at the price of $5.78 back on Aug 21 ’24. After this action, PAUL BOLNO now owns shares of Wave Life Sciences Ltd., valued at $279,638 using the latest closing price.
Moran Kyle, the Chief Financial Officer of Wave Life Sciences Ltd., sale 15,630 shares at $6.17 during a trade that took place back on Apr 03 ’24, which means that Moran Kyle is holding 33,921 shares at $96,421 based on the most recent closing price.
Stock Fundamentals for WVE
Current profitability levels for the company are sitting at:
- -0.76 for the present operating margin
- 0.92 for the gross margin
The net margin for Wave Life Sciences Ltd. stands at -0.67. The total capital return value is set at -2.34. Equity return is now at value -1928.16, with -33.61 for asset returns.
Based on Wave Life Sciences Ltd. (WVE), the company’s capital structure generated 0.87 points at debt to capital in total, while cash flow to debt ratio is standing at -4.44. The debt to equity ratio resting at 6.57. The interest coverage ratio of the stock is -29.06.
Currently, EBITDA for the company is -58.79 million with net debt to EBITDA at 1.62. When we switch over and look at the enterprise to sales, we see a ratio of 5.1. The receivables turnover for the company is 85.66for trailing twelve months and the total asset turnover is 0.53. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.99.
Conclusion
To wrap up, the performance of Wave Life Sciences Ltd. (WVE) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
